Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100
- 13 August 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (7), 871-884
- https://doi.org/10.1182/blood.2019003084
Abstract
Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+ T-cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1-infected individuals are asymptomatic and only 3-5% of carriers develop ATL. Here, we describe the contribution of aberrant DNA methylation to ATL leukemogenesis. HTLV-1-infected T-cells and their uninfected counterparts were separately isolated based on CADM1 and CD7 expression status, and differentially methylated positions (DMPs) specific to HTLV-infected T-cells were identified through genome-wide DNA methylation profiling. Accumulation of DNA methylation at hypermethylated DMPs correlated strongly with ATL development and progression. In addition, we identified 22 genes down-regulated due to promoter hypermethylation in HTLV-1-infected T-cells, including THEMIS, LAIR1, and RNF130, which negatively regulate T-cell receptor (TCR) signaling. Phosphorylation of ZAP-70, a transducer of TCR signaling, was dysregulated in HTLV-1-infected cell lines but was normalized by re-expression of THEMIS. Therefore, we hypothesized that DNA hypermethylation contributes to growth advantages in HTLV-1-infected cells during ATL leukemogenesis. To test this idea, we investigated the anti-ATL activities of OR-1200 and OR-2100 (OR21), novel decitabine (DAC) prodrugs with enhanced oral bioavailability. Both DAC and OR21 inhibited cell growth, accompanied by global DNA hypomethylation, in xenograft tumors established by implantation of HTLV-1-infected cells. OR21 was less hematotoxic than DAC, whereas tumor growth inhibition was almost identical between the two compounds, making it suitable for long-term treatment of ATL patient-derived xenograft mice. Our results demonstrate that regional DNA hypermethylation is functionally important for ATL leukemogenesis and an effective therapeutic target.This publication has 48 references indexed in Scilit:
- Genetic alterations in adult T‐cell leukemia/lymphomaCancer Science, 2017
- Treatment and survival among 1594 patients with ATLBlood, 2015
- Integrated molecular analysis of adult T cell leukemia/lymphomaNature Genetics, 2015
- Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphomaThe Lancet Oncology, 2014
- Human Viral Oncogenesis: A Cancer Hallmarks AnalysisCell Host & Microbe, 2014
- Multi-Step Aberrant CpG Island Hyper-Methylation Is Associated with the Progression of Adult T–Cell Leukemia/LymphomaThe American Journal of Pathology, 2010
- Promoter methylation of the bone morphogenetic protein‐6 gene in association with adult T‐cell leukemiaInternational Journal of Cancer, 2008
- Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformationNature Reviews Cancer, 2007
- Identification of Aberrantly Methylated Genes in Association with Adult T-Cell LeukemiaCancer Research, 2004
- Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cellsBlood, 2004